Article ; Online: Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Journal of medical case reports
2014 Volume 8, Page(s) 122
Abstract: Introduction: Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years. Response rates with chemotherapy ... ...
| Abstract | Introduction: Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years. Response rates with chemotherapy are modest and disease progression is usually observed within months of stopping treatment. Case presentation: We present a case of a 72-year-old White man of British origin with metastatic castrate-resistant prostate cancer with bulky lymphadenopathy and a serum prostate-specific antigen of 295 μg/L. He received treatment with docetaxel chemotherapy plus prednisolone, but received just 3 cycles before treatment was stopped due to toxicity and lack of response (prostate-specific antigen was 276 μg/L 4 weeks after the last dose and there was a confirmed stable appearance on computed tomography scan). Unexpectedly, at follow-up 4 months later, the patient was clinically better; his prostate-specific antigen had dramatically improved to 4.1 μg/L and a re-staging computed tomography scan revealed complete resolution of his bulky lymphadenopathy. At the time, he was receiving a luteinising hormone-releasing hormone analogue but no other disease-modulating treatment. He remains well and asymptomatic, with his most recent serum prostate-specific antigen measuring 0.14 μg/L, 18 months after last receiving chemotherapy. Conclusion: We report a case of complete and durable regression of metastatic castrate-resistant prostate cancer following palliative chemotherapy which, to the best of our knowledge, has not previously been reported in the literature. |
|---|---|
| MeSH term(s) | Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Aged ; Androgen Antagonists/therapeutic use ; Anilides/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Docetaxel ; Goserelin/therapeutic use ; Humans ; Lymphatic Metastasis ; Male ; Nitriles/therapeutic use ; Prostate/pathology ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Taxoids/therapeutic use ; Tosyl Compounds/therapeutic use ; Treatment Failure ; Treatment Outcome |
| Chemical Substances | Androgen Antagonists ; Anilides ; Antineoplastic Agents ; Antineoplastic Agents, Hormonal ; Nitriles ; Taxoids ; Tosyl Compounds ; Goserelin (0F65R8P09N) ; Docetaxel (15H5577CQD) ; bicalutamide (A0Z3NAU9DP) |
| Language | English |
| Publishing date | 2014-04-09 |
| Publishing country | England |
| Document type | Case Reports ; Journal Article |
| ZDB-ID | 2269805-X |
| ISSN | 1752-1947 ; 1752-1947 |
| ISSN (online) | 1752-1947 |
| ISSN | 1752-1947 |
| DOI | 10.1186/1752-1947-8-122 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.